文献速递头颈外科

免疫与靶向治疗时代头颈鳞癌新兴生物标志物综述

Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy.
PubMed 文献 · Head Neck · 2019-01-01

本综述批判性回顾并总结了近年同行评议证据,介绍HNSCC生物标志物的目的与分类(预测、预后、诊断)及开发阶段,按临床效用排序总结现有标志物,指出p16与HPV状态仍是最重要且经验证的标志物,并讨论液体活检等新兴方向及标准化需求。

要点

  • p16与HPV状态仍是HNSCC最重要且经验证的生物标志物。
  • 组织或血液生物标志物可指导新的抗癌治疗方向。
  • 非侵入性体液与液体活检标志物在早期检测、诊断、复发监测和预后预测方面潜力较大。

核心结论

  • 来自HNSCC癌组织或血液的生物标志物可指导新的抗癌治疗。

研究设计与样本

  • 对近年相关同行评议证据进行批判性回顾与总结的综述。

主要发现

  • 按临床效用顺序总结了当前HNSCC生物标志物。
  • p16与HPV状态仍是最重要且经验证的HNSCC生物标志物。
  • 非侵入性体液与液体活检标志物在早期癌症检测、诊断、复发监测和预后预测方面显示出较强开发潜力。

关键数值与推荐

  • 生物标志物按目的分为预测性、预后性和诊断性标志物。
  • 不同技术间存在差异,需要标准化方法。

临床怎么用

  • 临床可依据p16与HPV状态等经验证标志物辅助HNSCC诊疗决策。
  • 关注液体活检等非侵入性标志物在早期检测、复发监测和预后预测中的应用前景。

局限性

  • 不同技术间存在差异,标准化方法尚待建立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biomarkers in head and neck squamous cell carcinoma (HNSCC) emerge rapidly in recent years, especially for new targeted therapies and immunotherapies. METHODS: Recent, relevant peer-reviewed evidence were critically reviewed and summarized. RESULTS: This review article briefly introduces essential biomarker concepts, including purposes and classifications (predictive, prognostic, and diagnostic markers), and the phases of biomarker development. We summarize current biomarkers in order of clinical utility; p16 and human papillomavirus status remain the most important and validated biomarkers in HNSCC. The rationale for biomarker study design continues to evolve with technological advances, especially whole-exome or whole-genomic sequencing. Noninvasive body fluid and liquid biopsy biomarkers appear to hold strong potential for development as tools for early cancer detection, cancer diagnosis, monitoring of disease recurrence, and outcome prediction. In light of discrepancies among different technologies, standardized approaches are needed. CONCLUSION: Biomarkers from cancer tissue or blood in HNSCC could direct new anticancer therapies.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Hsieh JC, Wang HM, Wu MH, et al. Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy. Head Neck. 2019. PMID: 31573749. doi:10.1002/hed.25932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。